RxDoctor Payments Data

Guiling Yang, NP

Adult Health · Durham, NCNPI 1891033387

Payments from drug & device makers

$1,337in general payments, 2019–2025

Across 12 payments — averaging $111.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sequel Med Tech, LLC$202
  • Cequr Corporation$186
  • BETA Bionics, Inc.$172
  • Amgen$166
  • Novo Nordisk$126
  • Tandem Diabetes Care, Inc.$113
  • plus $372 from 4 others

What the payments were for

  • Food & beverage$1,337100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,337 in reported general payments places this provider in the 70th percentile of 614 adult health providers in North Carolina.

See all adult health providers in North Carolina

Medicare billing

Part B allowed, 2024
$49,811
Medicare patients
191
Services billed
911

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide601$879,500
JardianceEmpagliflozin427$472,056
MounjaroTirzepatide219$285,451
TrulicityDulaglutide170$243,658
FarxigaDapagliflozin Propanediol53$67,771
RybelsusSemaglutide36$56,156
Tresiba Flextouch U-100Insulin Degludec98$53,808
Tresiba Flextouch U-200Insulin Degludec37$35,607
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog33$33,523
Humalog Kwikpen U-200Insulin Lispro20$32,551
Humalog Kwikpen U-100Insulin Lispro147$31,796
Fiasp FlextouchInsulin Aspart (Niacinamide)47$28,150
Novolog FlexpenInsulin Aspart99$26,178
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog53$23,292
Insulin Lispro Kwikpen U-100Insulin Lispro78$19,897

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Tresiba, Novolog$126$944,886665 claims
Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Humalog$109$537,736418 claims
AstraZenecaFarxiga$58$67,77153 claims
Sanofi-aventis U.S. LLCLantus$91$1,45123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 614 adult health providers in North Carolina.

Other adult health in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →